Mathieu Kerneis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mathieu Kerneis has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:
- Lee S. Nguyen
Intensive Care Medicine Department, CMC Ambroise Paré, Neuilly-sur-Seine, France
82 shared publications - Yves Allenbach
Department of Internal Medicine and Clinical Immunology, Hôpital Pitié-Salpêtrière, Assistance Publique—Hôpitaux de Paris, Sorbonne Université , Paris
81 shared publications - Estelle Gandjbakhch
Sorbonne Université, APHP, La Pitié Salpetrière University Hospital , Paris
80 shared publications - Joe-Elie Salem
Sorbonne Universite, Institut National de la Sante et de la Recherche Medicale, CIC-2503, Assistance Publique-Hopitaux de Paris, Pitié-Salpêtrière Hospital, Department of Pharmacology, France
80 shared publications - Alban Redheuil
Sorbonne University, Department of Cardiovascular and Thoracic Radiology, Hôpital de la Pitié-Salpêtrière (AP-HP), Institute of Cardiometabolism and Nutrition (ICAN), Paris, France; Sorbonne University, Biomedical Imaging Laboratory (LIB), INSERM, CNRS, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France
79 shared publications - Guillaume Hekimian
Sorbonne Université, AP-HP, Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive Réanimation , Paris
79 shared publications
Latest Publications
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 741-751
Prognostic impact of pericardial effusion in patients with acute myocarditis
Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.
- 31 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 741-751
Prognostic impact of pericardial effusion in patients with acute myocarditis
Aims: Recent Guidelines of the European Society of Cardiology have introduced the concept of Inflammatory Myocardial and Pericardial Syndrome (IMPS), a unified entity encompassing both myocarditis and pericarditis. This framework reflects the continuum between these conditions in term of anatomy, shared aetiologies, and a common diagnostic approach. This study sought (i) to describe factors associated with pericardial involvement; (ii) to compare the outcomes of patients hospitalized for proven acute myocarditis (AM) with or without pericardial effusion; (iii) to identify the independent correlates of clinical outcome. Methods and results: This is an observational ambispective cohort study based on the AMPHIBIA registry (Assistance Publique—Hôpitaux de Paris/ACTION Study Group), including patients hospitalized for proven AM between August 2008 and December 2024 at La Pitié Salpêtrière Hospital, Paris, France. Patients were stratified into two groups based on the presence of pericardial effusion on admission transthoracic echocardiography, ranging from minimal effusions to tamponade. The main composite outcome was defined as the occurrence of all-cause death, temporary mechanical circulatory support, severe ventricular arrhythmia, and heart transplantation, at the longest follow-up, up to 7 years. A total of 581 patients with AM were included [follow-up 3.7 (1.3–7.3) years]. Among them, 134 (23%) patients presented with pericardial effusion and 447 (77%) patients without. Four independent variables were associated with pericardial effusion at admission: left ventricular (LV) dysfunction, immunological myocarditis, elevated CRP, and fever. The occurrence of the composite event was significantly higher in patients with pericardial effusion compared to those without [38.1% vs. 15.7%, hazard ratio (HR) 2.69, 95% confidence interval (CI) (1.88–3.86), P < 0.001]. This difference was observed regardless of pericardial effusion size. After multivariable analysis, pericardial effusion was independently associated with the main composite outcome [HR 1.99 (1.32–3.00), P < 0.001. Conclusion: This study characterizes the phenotypes and outcomes of patients hospitalized for an AM, with and without pericardial effusion. Pericardial involvement was associated with LV dysfunction, immunological myocarditis, elevated CRP, and fever and was linked to a markedly higher risk of the composite outcome, remaining an independent predictor of adverse events. Differentiating these two phenotypes may provide physicians with valuable guidance for managing therapy in these patients.
- 31 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 788-803
Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the European Society of Cardiology Council on Basic Cardiovascular Science, and the European Society of Cardiology Council for Cardiology Practice
Inflammation is a key driver of coronary syndromes across the continuum from chronic coronary syndromes to acute coronary syndromes. It contributes to atherogenesis, plaque destabilization, and ischaemic events and influences myocardial injury, repair, and remodelling. Inflammatory activity is further amplified by metabolic and autoimmune comorbidities such as diabetes, obesity, and connective tissue diseases, with obesity representing a major driver of chronic low-grade inflammation through adipose tissue dysfunction and cytokine activation, while psychosocial stress and environmental exposures including air pollution serve as additional triggers. Genetic variations, including human leucocyte antigen genotypes, modulate individual susceptibility to vascular inflammation and myocardial injury. This expert consensus from the European Society of Cardiology’s Association for Acute CardioVascular Care summarizes the current understanding of inflammation across the full spectrum of coronary syndromes, including underlying mechanisms, relevant biomarkers, and imaging approaches that characterize vascular inflammation, and integrates insights from experimental and clinical studies. Importantly, this document provides explicit consensus-based guidance on when, how, and in whom inflammation should be assessed and treated in routine clinical practice. While the causal association between inflammation and atherosclerotic cardiovascular disease is well established, pharmacological modification of inflammation has produced conflicting evidence. Some agents, such as low-dose colchicine, have demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent. Other anti-inflammatory therapies have not shown clinical benefit, whereas selective cytokine inhibition with canakinumab has reduced cardiovascular risk at the cost of increased infection rates. The present manuscript also focuses on the evaluation of inflammatory activity in cardiovascular patients in routine clinical practice. It further discusses criteria for patient selection and clinical decision-making regarding the introduction of anti-inflammatory therapy in individuals with established atherosclerotic cardiovascular disease.
- 31 July 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
- Vol. 15 (10) , 788-803
Inflammation in coronary syndromes in clinical practice: a clinical consensus statement of the Association for Acute Cardiovascular Care of the European Society of Cardiology, the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases, the European Society of Cardiology Council on Basic Cardiovascular Science, and the European Society of Cardiology Council for Cardiology Practice
Inflammation is a key driver of coronary syndromes across the continuum from chronic coronary syndromes to acute coronary syndromes. It contributes to atherogenesis, plaque destabilization, and ischaemic events and influences myocardial injury, repair, and remodelling. Inflammatory activity is further amplified by metabolic and autoimmune comorbidities such as diabetes, obesity, and connective tissue diseases, with obesity representing a major driver of chronic low-grade inflammation through adipose tissue dysfunction and cytokine activation, while psychosocial stress and environmental exposures including air pollution serve as additional triggers. Genetic variations, including human leucocyte antigen genotypes, modulate individual susceptibility to vascular inflammation and myocardial injury. This expert consensus from the European Society of Cardiology’s Association for Acute CardioVascular Care summarizes the current understanding of inflammation across the full spectrum of coronary syndromes, including underlying mechanisms, relevant biomarkers, and imaging approaches that characterize vascular inflammation, and integrates insights from experimental and clinical studies. Importantly, this document provides explicit consensus-based guidance on when, how, and in whom inflammation should be assessed and treated in routine clinical practice. While the causal association between inflammation and atherosclerotic cardiovascular disease is well established, pharmacological modification of inflammation has produced conflicting evidence. Some agents, such as low-dose colchicine, have demonstrated modest reductions in cardiovascular events, although results across trials have been inconsistent. Other anti-inflammatory therapies have not shown clinical benefit, whereas selective cytokine inhibition with canakinumab has reduced cardiovascular risk at the cost of increased infection rates. The present manuscript also focuses on the evaluation of inflammatory activity in cardiovascular patients in routine clinical practice. It further discusses criteria for patient selection and clinical decision-making regarding the introduction of anti-inflammatory therapy in individuals with established atherosclerotic cardiovascular disease.
- Open Access
- 6 May 2026
- Vol. 28 (5)
Incidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.
Long-term arrhythmic risk after myocarditis remains uncertain, and optimal management is debated. We aimed to assess the incidence and predictors of major arrhythmic events (MAEs) after myocarditis. We conducted a systematic literature review and meta-analysis including 19 observational studies on myocarditis and MAEs during follow-up. Major arrhythmic events were defined as a composite of sudden cardiac death (SCD), ventricular fibrillation (VF), aborted cardiac arrest (ACA), sustained ventricular tachycardia (sVT), and appropriate implantable cardioverter defibrillator (ICD) or wearable-cardioverter defibrillator (WCD) intervention. The primary outcome was the incidence of MAEs after discharge; secondary outcomes included occurrence of each component of MAEs and the composite of all-cause mortality or heart transplantation (HTx). Three thousand nine hundred and fifty-four patients (71% male, 67% acute, 88% complicated myocarditis) were included. At presentation, 15% had high-grade atrioventricular block (AVB), 31% heart failure, 38% MAEs. At a median follow-up of 24 months (interquartile range 19-57), 28% suffered MAEs, with a median time of presentation of 12 months. The incidence of sVT, ACA/VF, appropriate ICD/WCD intervention, and SCD were 22%, 6%, 20%, and 1%, respectively. The combined rate of all-cause mortality/HTx was 11%. At meta-regression analysis, high-grade AVB, MAEs at presentation, and fulminant myocarditis were associated with higher risk of MAEs during follow-up, while male gender resulted as a protective factor. The incidence of MAEs after a complicated acute myocarditis can be high over time. Further prospective studies are needed to better stratify high-risk patients, identify those with an underlying arrhythmogenic cardiomyopathy, and guide antiarrhythmic strategies.
- 6 May 2026
- Vol. 28 (5)
Open AccessIncidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.
Long-term arrhythmic risk after myocarditis remains uncertain, and optimal management is debated. We aimed to assess the incidence and predictors of major arrhythmic events (MAEs) after myocarditis. We conducted a systematic literature review and meta-analysis including 19 observational studies on myocarditis and MAEs during follow-up. Major arrhythmic events were defined as a composite of sudden cardiac death (SCD), ventricular fibrillation (VF), aborted cardiac arrest (ACA), sustained ventricular tachycardia (sVT), and appropriate implantable cardioverter defibrillator (ICD) or wearable-cardioverter defibrillator (WCD) intervention. The primary outcome was the incidence of MAEs after discharge; secondary outcomes included occurrence of each component of MAEs and the composite of all-cause mortality or heart transplantation (HTx). Three thousand nine hundred and fifty-four patients (71% male, 67% acute, 88% complicated myocarditis) were included. At presentation, 15% had high-grade atrioventricular block (AVB), 31% heart failure, 38% MAEs. At a median follow-up of 24 months (interquartile range 19-57), 28% suffered MAEs, with a median time of presentation of 12 months. The incidence of sVT, ACA/VF, appropriate ICD/WCD intervention, and SCD were 22%, 6%, 20%, and 1%, respectively. The combined rate of all-cause mortality/HTx was 11%. At meta-regression analysis, high-grade AVB, MAEs at presentation, and fulminant myocarditis were associated with higher risk of MAEs during follow-up, while male gender resulted as a protective factor. The incidence of MAEs after a complicated acute myocarditis can be high over time. Further prospective studies are needed to better stratify high-risk patients, identify those with an underlying arrhythmogenic cardiomyopathy, and guide antiarrhythmic strategies.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Risques et bénéfices des stratégies associant anticoagulants et antiagrégants plaquettaires chez le patient coronarien
Cette thèse suggère que la bithérapie nouvel anticoagulant oral et clopidogrel doit être la règle chez les patients stentés nécessitant une anticoagulation au long cours. Cette bithérapie est supérieure à une trithérapie comprenant un antagoniste de la vitamine K et une double antiagrégation plaquettaire sur la réduction du risque hémorragique, avec un risque ischémique similaire, sans que la gravité de la maladie coronaire, la complexité de l’angioplastie, ou l’équilibre de l’INR n’interagissent sur ce résultat. Le bénéfice clinique de cette stratégie est aussi démontré en comparaison à une bithérapie comprenant un antagoniste de la vitamine K et une simple antiagrégation plaquettaire. Cette thèse démontre également que l’utilisation du rivaroxaban est associée à une réduction du taux plasmatique de D-Dimères du risque d’évènements athérothrombotiques. Au-delà, des marqueurs classiques de thrombose, la mesure de l’interleukine-1beta au sein d’une cohorte de patient présentant un infarctus, permettait de prédire la survenue d’évènement athérothrombotique. Dans ce contexte, le type d’anticoagulation parentérale, dont le choix était laissé à l’appréciation de l’investigateur dans l’étude ATLANTIC, n’était pas associé à la survenue d’événements cliniques. Néanmoins, l’évaluation de la balance bénéfice/risque des antithrombotiques, classiquement basée sur l’évaluation du bénéfice clinique net, peut désormais tirer bénéfice d’outils mathématiques plus performant prenant en compte à la fois la réduction du risque de saignement et la recherche de non-infériorité sur le critère ischémique, comme démontrée dans l’analyse bivariée ou l’utilisation de machine learning.
- 7 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
Risques et bénéfices des stratégies associant anticoagulants et antiagrégants plaquettaires chez le patient coronarien
Cette thèse suggère que la bithérapie nouvel anticoagulant oral et clopidogrel doit être la règle chez les patients stentés nécessitant une anticoagulation au long cours. Cette bithérapie est supérieure à une trithérapie comprenant un antagoniste de la vitamine K et une double antiagrégation plaquettaire sur la réduction du risque hémorragique, avec un risque ischémique similaire, sans que la gravité de la maladie coronaire, la complexité de l’angioplastie, ou l’équilibre de l’INR n’interagissent sur ce résultat. Le bénéfice clinique de cette stratégie est aussi démontré en comparaison à une bithérapie comprenant un antagoniste de la vitamine K et une simple antiagrégation plaquettaire. Cette thèse démontre également que l’utilisation du rivaroxaban est associée à une réduction du taux plasmatique de D-Dimères du risque d’évènements athérothrombotiques. Au-delà, des marqueurs classiques de thrombose, la mesure de l’interleukine-1beta au sein d’une cohorte de patient présentant un infarctus, permettait de prédire la survenue d’évènement athérothrombotique. Dans ce contexte, le type d’anticoagulation parentérale, dont le choix était laissé à l’appréciation de l’investigateur dans l’étude ATLANTIC, n’était pas associé à la survenue d’événements cliniques. Néanmoins, l’évaluation de la balance bénéfice/risque des antithrombotiques, classiquement basée sur l’évaluation du bénéfice clinique net, peut désormais tirer bénéfice d’outils mathématiques plus performant prenant en compte à la fois la réduction du risque de saignement et la recherche de non-infériorité sur le critère ischémique, comme démontrée dans l’analyse bivariée ou l’utilisation de machine learning.
- Open Access
- 16 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Impact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study
Introduction: Cannabidiol has been shown to exert significant anti-inflammatory effects and has demonstrated efficacy in murine models of autoimmune myocarditis, pericarditis, and heart failure. The ARCHER Study assessed whether a pharmaceutically produced cannabidiol formulation showed beneficial effects on cardiac magnetic resonance (CMR) endpoints known to predict prognosis in this patient population. Methods: In a multicentre international double-blind placebo-controlled phase 2 study, we randomly assigned 109 patients within 10 days of CMR confirmed diagnosis of acute myocarditis to 12 weeks of pharmaceutically produced oral cannabidiol (active) or placebo. Dose was titrated up to 10 mg/kg of body weight twice daily. Primary endpoints were the difference in extracellular volume (ECV) and global longitudinal strain (GLS) measured by CMR at week 12. Other CMR endpoints included left-ventricular ejection fraction (LVEF), LV mass, intracellular volume (ICV), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), and left-atrial end-systolic volume (LAESV). Results: All randomized patients (56 active/53 placebo) completed the study with no loss to follow-up. Study drug appeared safe and well tolerated. Baseline mean ECV 38.9 ± 10.9 ml, GLS −15.3 ± 3.6%, and LVEF 60.6 ± 9.9% were consistent with mild to moderate myocarditis and predominantly intact LV function. Week 12 mean ECV was 33.6 ml in the active group and 37.3 ml in the placebo group, a difference of −3.7 ml, confidence interval (CI): −7.4 to 0.1; P = .0538; GLS was −16.0% in the active group and −15.9% in the placebo group, difference of −0.1, CI: −1.2 to 1.1; P = .90. Left ventricular mass was significantly reduced in the active group at 121.1 g compared to placebo 130.3 g, a difference of −9.2, CI: −16.4 to −2.1; P = .0117. In terms of remodelling, LAESV was significantly reduced in the active group (−8.1 ml; P = .0376) while the reduction in LVEDV failed to reach significance (−7.4 ml; P = .098). Conclusion: In mild-to-moderate acute myocarditis, treatment with pharmaceutically manufactured cannabidiol was not associated with a statistically significant change in myocardial ECV or GLS, although a trend towards reduction in ECV was observed. In addition, improvement in other potential markers of myocardial recovery, including a significant reduction in LV mass, was seen in the active treatment group. Further investigation of the therapeutic potential of this therapy in inflammatory cardiac conditions is warranted.
- 16 January 2026
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 13 (1)
Open AccessImpact of cannabidiol on myocardial recovery in patients with acute myocarditis: primary results of the ARCHER study
Introduction: Cannabidiol has been shown to exert significant anti-inflammatory effects and has demonstrated efficacy in murine models of autoimmune myocarditis, pericarditis, and heart failure. The ARCHER Study assessed whether a pharmaceutically produced cannabidiol formulation showed beneficial effects on cardiac magnetic resonance (CMR) endpoints known to predict prognosis in this patient population. Methods: In a multicentre international double-blind placebo-controlled phase 2 study, we randomly assigned 109 patients within 10 days of CMR confirmed diagnosis of acute myocarditis to 12 weeks of pharmaceutically produced oral cannabidiol (active) or placebo. Dose was titrated up to 10 mg/kg of body weight twice daily. Primary endpoints were the difference in extracellular volume (ECV) and global longitudinal strain (GLS) measured by CMR at week 12. Other CMR endpoints included left-ventricular ejection fraction (LVEF), LV mass, intracellular volume (ICV), LV end-diastolic and end-systolic volumes (LVEDV, LVESV), and left-atrial end-systolic volume (LAESV). Results: All randomized patients (56 active/53 placebo) completed the study with no loss to follow-up. Study drug appeared safe and well tolerated. Baseline mean ECV 38.9 ± 10.9 ml, GLS −15.3 ± 3.6%, and LVEF 60.6 ± 9.9% were consistent with mild to moderate myocarditis and predominantly intact LV function. Week 12 mean ECV was 33.6 ml in the active group and 37.3 ml in the placebo group, a difference of −3.7 ml, confidence interval (CI): −7.4 to 0.1; P = .0538; GLS was −16.0% in the active group and −15.9% in the placebo group, difference of −0.1, CI: −1.2 to 1.1; P = .90. Left ventricular mass was significantly reduced in the active group at 121.1 g compared to placebo 130.3 g, a difference of −9.2, CI: −16.4 to −2.1; P = .0117. In terms of remodelling, LAESV was significantly reduced in the active group (−8.1 ml; P = .0376) while the reduction in LVEDV failed to reach significance (−7.4 ml; P = .098). Conclusion: In mild-to-moderate acute myocarditis, treatment with pharmaceutically manufactured cannabidiol was not associated with a statistically significant change in myocardial ECV or GLS, although a trend towards reduction in ECV was observed. In addition, improvement in other potential markers of myocardial recovery, including a significant reduction in LV mass, was seen in the active treatment group. Further investigation of the therapeutic potential of this therapy in inflammatory cardiac conditions is warranted.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Examples of cardiac and skeletal muscle pathology findings on autopsies of 2 patients
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Examples of cardiac and skeletal muscle pathology findings on autopsies of 2 patients
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S6 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Treatment modalities and reported adverse events by quartile of period of inclusion.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Treatment modalities and reported adverse events by quartile of period of inclusion.
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Methods concerning Immune-checkpoint proteins profiling on peripheral blood mononuclear cells and Circulating immune checkpoint agents drug monitoring
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Methods concerning Immune-checkpoint proteins profiling on peripheral blood mononuclear cells and Circulating immune checkpoint agents drug monitoring
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Proposed management algorithm for ICI-myotoxicities as a function of severity criteria grading
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Proposed management algorithm for ICI-myotoxicities as a function of severity criteria grading
- Open Access
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Delay between presentation for ICI myocarditis, appearance of life-threatening myotoxicity criteria (severity grade 4, Supplementary Table 5 for details concerning grading) and start of the immunosuppressive treatments (with dose) in severe ICI-myocarditis patients requiring abatacept.
- 11 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis
Delay between presentation for ICI myocarditis, appearance of life-threatening myotoxicity criteria (severity grade 4, Supplementary Table 5 for details concerning grading) and start of the immunosuppressive treatments (with dose) in severe ICI-myocarditis patients requiring abatacept.